Antibiotic Discovery and Development

1. The Early History of Antibiotic Discovery: Empiricism Ruled
Richard J. White

2. Rational Approaches to Antibacterial Discovery: Pre-Genomic Directed and Phenotypic Screening
Lynn L. Silver

3. Beta-Lactam Antibiotics
Malcolm G. P. Page

4. Review of the Quinolone Family
George A. Jacoby, David C. Hooper

5. Tetracyclines
Patricia A. Bradford, C. Hal Jones

6. Macrolides and Ketolides
Ze-Qi Xu, Michael T. Flavin, David A. Eiznhamer

7. Aminoglycosides
Eliana S. Armstrong, Corwin F. Kostrub, Robert T. Cass, Heinz E. Moser, Alisa W. Serio, George H. Miller

8. Oxazolidinone Antibacterial Agents
Michael R. Barbachyn

9. Glycopeptides and Lipoglycopeptides
F. F. Arhin, A. Belley, A. Rafai Far, D. Lehoux, G. Moeck, T. R. Parr

10. Efflux-Mediated Antimicrobial Resistance
Keith Poole

11. Structural Mechanisms of β-Lactam Antibiotic Resistance in Penicillin-Binding Proteins
Robert A. Nicholas, Christopher Davies

12. Evolution of β-Lactamases: Past, Present, and Future
Karen Bush

13. Inducible Resistance to Macrolide Antibiotics
Sai Lakshmi Subramanian, Haripriya Ramu, Alexander S. Mankin

14. Fluoroquinolone Resistance: Mechanisms, Restrictive Dosing, and Anti-Mutant Screening Strategies for New Compounds
Karl Drlica, Xilin Zhao, Muhammad Malik, Tal Salz, Robert Kerns

15. Glycopeptide Resistance
Bruno Périchon, Patrice Courvalin

16. Acquired Tetracycline Resistance Genes
Marilyn C. Roberts

17. Evolution of Molecular Techniques for the Characterization of MRSA Clones
Duarte C. Oliveira, Hermínia Lencastre, Alexander Tomasz

18. Mechanisms of Penicillin Resistance in Streptococcus pneumoniae: Targets, Gene Transfer and Mutations
Regine Hakenbeck, Dalia Denapaite, Patrick Maurer

19. Clinical Aspects of Multi-Drug Resistant Enterococci
German A. Contreras, Cesar A. Arias

20. Clinical Issues of Resistance: Problematic Microbes: Enterobacteriaceae
David F. Briceño, Julián A. Torres, José D. Tafur, John P. Quinn, María V. Villegas

21.
Pseudomonas aeruginosa: A Persistent Pathogen in Cystic Fibrosis and Hospital-Associated Infections
Kristen N. Schurek, Elena B. M. Breidenstein, Robert E. W. Hancock

22. Drug Resistant and Persistent Tuberculosis: Mechanisms and Drug Development
Ying Zhang

23. Resistance Trends and Susceptibility Profiles in the US Among Prevalent Clinical Pathogens: Lessons from Surveillance
Chris Pillar, Dan Sahm

24. Chemical Properties of Antimicrobials and Their Uniqueness
Mark J. Macielag

25. Natural Products in the 21st Century
Sheo B. Singh

26. Permeability of Bacteria to Antibacterial Agents
Wright W. Nichols

27. Novel Antibacterial Targets/Identification of New Targets by Comparative Genomics
Sarah M. McLeod, Thomas J. Dougherty, Michael J. Pucci

28. Cell-Based Screening in Antibacterial Discovery
Scott D. Mills, Thomas J. Dougherty

29. Enzyme-Based Screens in HTS
David E. Ehmann, Stewart L. Fisher

30. Antibacterial Inhibitors of the Essential Cell Division Protein FtsZ
Lloyd G. Czaplewski, Neil R. Stokes, Steve Ruston, David J. Haydon

31. Structure-Guided Discovery of New Antimicrobial Agents
Molly B. Schmid

32. NMR in Infection Research
Jun Hu, Gunther Kern

33. A Review of Animal Models Used for Antibiotic Evaluation
Andrea Marra

34. In Vivo Pharmacodynamic Modeling for Drug Discovery
Jared L. Crandon, David P. Nicolau

35. Applications of Pharmacokinetic/Pharmacodynamic Models for the Development of Antimicrobial Agents
April Barbour, Hartmut Derendorf

36. Antibiotic Drug Development: Moving Forward into the Clinic
Jane E. Ambler, Greg G. Stone

37. Stimulating Antibacterial Research and Development: Sense and Sensibility?
Steven J. Projan

Nyckelord: Biomedicine, Medical Microbiology, Pharmacology/Toxicology, Physical Chemistry, Molecular Medicine